Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CR6261 in Healthy Japanese Subjects
NCT02016066Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2013
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Influenza A infection comparing CR6261 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events up to 76 days. Planned start Dec 2013; status: withdrawn.
02
Drugs
diridavumab
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on NCT02016066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016066.